The short version of IRAP fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-20. Anything still debated is marked as such rather than presented as settled.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
=== Zinc(I) compounds === Zinc(I) compounds are very rare. The [Zn2]2+ ion is implicated by the formation of a yellow diamagnetic glass by dissolving metallic zinc in molten ZnCl2. The [Zn2]2+ core would be analogous to the [Hg2]2+ cation present in mercury(I) compounds. The diamagnetic nature of the ion confirms its dimeric structure. The first zinc(I) compound containing the Zn–Zn bond, (η5-C5Me5)2Zn2 has been reported in 2004.
=== Anti-DFS70 antibodies === Anti-DFS70 antibodies generate a dense fine speckled pattern in indirect immunofluorescence and are found in normals and in various conditions, but are not associated with a systemic autoimmune pathology. Therefore, they can be used to help to rule out such conditions in ANA positive individuals. A significant number of patients are diagnosed as systemic lupus erythematosus or undifferentiated connective tissue disease largely based on a positive ANA. In case no defined autoantibody can be detected (e.g. anti-ENA antibodies), the testing of anti-DFS70 antibodies is recommended to verify the diagnosis. Anti-DFS70 antibody tests are available as CE-marked tests. Until now, no FDA cleared assay is available.
The liver is a vital organ and supports almost every other organ in the body. Severe or end-stage liver failure has dire consequences for the body's overall health and quality of life. Visible signs of liver disease include jaundice and ascites. Hepatomegaly refers to an enlarged liver and may be caused by several underlying diseases. It can be palpated in an abdominal exam. Scarring (fibrosis) of the liver from any cause can lead to cirrhosis. Cirrhosis increases the resistance to blood flow in the liver, and can result in portal hypertension. Congested anastomoses between the portal venous system and the systemic circulation, can be a subsequent condition. The most common chronic liver disease is nonalcoholic fatty liver disease, which affects an estimated one-third of the world population. Hepatitis is a common condition of inflammation of the liver. The cause is usually viral, and the most common of these infections are hepatitis A, B, C, D, and E. Some of these infections are transmitted sexually or through non-sterile needles. Inflammation can also be caused by other viruses in the family Herpesviridae such as the herpes simplex virus. Chronic (rather than acute) infection with hepatitis B virus or hepatitis C virus is the main cause of liver cancer. Globally, about 248 million individuals are chronically infected with hepatitis B (with 843,724 in the U.S.), and 142 million are chronically infected with hepatitis C (with 2.7 million in the U.S.).
methyl Also carbinyl. The alkyl functional group derived from methane, consisting of one carbon atom bonded to three hydrogen atoms, with the chemical formula CH3. It is the simplest hydrocarbon and occurs as a substituent in numerous organic compounds, though it may also exist independently as an ion or radical. In IUPAC nomenclature, the presence of a methyl substituent is indicated with the prefix methyl in the name of the compound, or with the abbreviation Me in chemical formulae; e.g. methyl alcohol (methanol) is often written with the formula CH3OH or MeOH.
== Biological role == Surface proteins of Gram-positive bacteria play an important role in the pathogenesis of human infections such as Clostridioides difficile infection. These surface/adhesion proteins mediate the initial attachment of bacteria to host tissues. These proteins are covalently linked to the peptidoglycan of the bacterial cell wall. As more and more pathogens become resistant to antibiotics, inhibition of sortases may offer a novel strategy against gram-positive bacterial infections. SrtB, in particular, has gained much attention and is recognized as a promising target and deletion of its gene in gram-positive bacteria will lead to serious virulence defects. Crystal structures of these SrtB enzymes from different species have been solved with ligands/inhibitors bound to their active site. With knowledge of the active site, the development of better therapeutics against these bacteria species can be done.
Sources: en.wikipedia.org
=== Phase 2 === BAER-101 (AZ-7325; AZD-7325) – selective GABAA α2 and α3 subunit-containing receptor positive allosteric modulator and nonbenzodiazepine/cinnoline Brexanolone caprilcerbate (Glyph Allopregnanolone; GlyphAllo; LYT-300; SPT-300; allopregnanolone prodrug) – GABAA receptor positive allosteric modulator and neurosteroid (brexanolone prodrug) [4] Cannabidiol (CBD; Arvisol) – cannabinoid receptor modulator and other actions [5] Cenobamate (ONO-2017; Ontozry; X-Copri; Xcopri; YKP-3089) – atypical voltage-gated sodium channel blocker and GABAA receptor positive allosteric modulator [6] ENX-102 (ENX102) — α2, α3, and α5 subunit-containing GABAA receptor positive allosteric modulator and nonbenzodiazepine JNJ-42165279 (JNJ-5279) – fatty acid amide hydrolase (FAAH) inhibitor [7] Maritupirdine (CD-008-0045) – serotonin 5-HT6 receptor antagonist [8] Psilocybin low dose (APEX-52) – non-selective serotonin receptor agonist and psychedelic hallucinogen [9] Vortioxetine (Brintellix; Lu-AA21004; trintellix; Vortidif) – serotonin reuptake inhibitor, serotonin 5-HT1A and 5-HT1B receptor agonist, and serotonin 5-HT1D, 5-HT3, and 5-HT7 receptor antagonist [10] Zuranolone (BIIB-125; S-812217; SAGE-217; SGE-797; Zurzuvae) – GABAA receptor positive allosteric modulator and neurosteroid [11]
=== Other genitourinary infections === Methenamine is converted into formaldehyde only in acidic environments like the urinary bladder and hence is not expected to be effective in the eradicative treatment of pyelonephritis (kidney infection) or chronic bacterial prostatitis. As a result, it is not recommended for such indications. However, methenamine may help to prevent pyelonephritis and hospitalization by preventing UTIs that can lead to these complications. In addition, in men with persistent or recurring chronic bacterial prostatitis, prophylactic methenamine may be useful as an alternative to low-dose prophylactic antibiotics in preventing prostatitis-derived UTIs and managing associated symptoms. Prophylactic low-dose methenamine combined with an ascorbic acid (vitamin C) supplement has been reported to be effective for this purpose based on clinical experience. In any case, supporting data for this use are lacking as of 2020.
Several studies have suggested that breast milk can pass antibodies to the infant for as long as the child continues to nurse. The antibodies may be in the mother's system as a result of being ill, or they may be acquired by drinking milk from a mother who has recently been vaccinated for a particular disease. One small study done on nursing mothers who had received the COVID-19 vaccine found that breastmilk continued to contain antibodies for as long as 80 days after receiving the vaccine.
=== Elderly === An increasing trend of anorexia among the elderly, termed "Anorexia of Aging", is observed, characterized by behaviors similar to those seen in typical anorexia nervosa but often accompanied by excessive laxative use. Most geriatric anorexia patients limit their food intake to dairy or grains, whereas an adolescent anorexic has a more general limitation. This eating disorder that affects older adults has two types – early onset and late onset. Early onset refers to a recurrence of anorexia in late life in an individual who experienced the disease during their youth. Late onset describes instances where the eating disorder begins for the first time late in life. The stimulus for anorexia in elderly patients is typically a loss of control over their lives, which can be brought on by many events, including moving into an assisted living facility. This is also a time when most older individuals experience a rise in conflict with family members, such as limitations on driving or limitations on personal freedom, which increases the likelihood of an issue with anorexia. There can be physical issues in the elderly that leads to anorexia of aging, including a decline in chewing ability, a decline in taste and smell, and a decrease in appetite. Psychological reasons for the elderly to develop anorexia can include depression and bereavement, and even an indirect attempt at suicide.
Sources: en.wikipedia.org
==== High blood pressure ==== Over 60% of cats with kidney disease develop high blood pressure. Amlodipine is the main drug used for treatment. If the antihypertensive effect is not sufficient, the AT1 antagonist, which has been approved for cats since 2014 telmisartan can also be used to treat high blood pressure and proteinuria. Telmisartan can significantly reduce the extent of proteinuria. However, the active ingredient can only be used as the sole antihypertensive agent if the blood pressure is below 200 mg Hg. It is important to monitor the effect of telmisartan at the beginning and after one week if the dose is changed by determining creatitinine, blood pressure and potassium levels; after four weeks, the urine protein-creatinine quotient should be checked. The reduction in systolic blood pressure must not be lowered below 120 mm Hg; it should be around 140 mm Hg. Telmisartan should also be discontinued in phases of volume or fluid deficiency, during acute episodes of illness or before anesthesia. ACE inhibitors such as benazepril, enalapril or ramipril alone do not usually lead to a sufficient reduction in blood pressure, but they can slow down the progression of the disease up to stage III. In stage IV, ACE inhibitors are considered relatively contraindicated. Of these active substances, benazepril and ramipril are currently approved for cats in Germany, all others must be reclassified. Dietetically, the tendency to high blood pressure can be reduced by reducing the sodium content of the feed.
=== Synthesis === One synthesis method (shown first) is based on N,N'-dicyclohexylcarbodiimide (DCC) assisted esterification of N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine with N-hydroxysuccinimide, followed by a condensation with 2-aminoethyl-2,3-dipalmitoylglycerylphosphoric acid in triethylamine (Et3N). A different approach (shown second) uses N-acetylmuramyl-L-alanyl-D-isoglutamine, hydroxysuccinimide and alanyl-2-aminoethyl-2,3-dipalmitoylglycerylphosphoric acid; that is, the alanine is introduced in the second step instead of the first.
Naturally occurring tungsten (74W) consists of five isotopes. Four are considered stable (182W, 183W, 184W, and 186W) and one is slightly radioactive, 180W, with an extremely long half-life of (1.59±0.05)×1018 years. This results in about two alpha decays of 180W per gram of natural tungsten per year, so for most practical purposes, 180W can be considered stable. The other naturally occurring isotopes are also capable of alpha decay and so only observationally stable. Artificial radioisotopes of tungsten have been observed from 156W to 197W, the most stable of which are 181W with a half-life of 120.96 days, 185W with a half-life of 75.1 days, 188W with a half-life of 69.77 days and 178W with a half-life of 21.6 days. All of the remaining radioactive isotopes have half-lives less than one day, and most of these less than 8 minutes. The most stable known meta state is 179m1W with half-life 6.40 minutes.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.